Changweiqing Cediates CXCR4/CXCL12 Signal Pathway to Intervene Liver Metastasis of Colorectal Cancer in Mice
|更新时间:2024-01-04
|
Changweiqing Cediates CXCR4/CXCL12 Signal Pathway to Intervene Liver Metastasis of Colorectal Cancer in Mice
Chinese Journal of Experimental Traditional Medical FormulaeVol. 18, Issue 23, Pages: 242-247(2012)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2012
稿件说明:
移动端阅览
WU Dong-hui, ZHU Yan-wei. Changweiqing Cediates CXCR4/CXCL12 Signal Pathway to Intervene Liver Metastasis of Colorectal Cancer in Mice[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 242-247.
DOI:
WU Dong-hui, ZHU Yan-wei. Changweiqing Cediates CXCR4/CXCL12 Signal Pathway to Intervene Liver Metastasis of Colorectal Cancer in Mice[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 242-247.DOI:
Changweiqing Cediates CXCR4/CXCL12 Signal Pathway to Intervene Liver Metastasis of Colorectal Cancer in Mice
Objective: To observe the inhibitory effect of Changweiqing on liver metastasis of colorectal cancer in mice
and investigate the related mechanism of Changweiqing on liver metastases of colorectal cancer
by Chemokine Ligand 12 (CXCL12)/Chemokine Receptor 4 (CXCR4)the signal transduction pathway and the expression of Matrix metalloproteinase 9(MMP9). Method: We established the liver metastases model of mice with implanted colon cancer CT26.Mice were divided into four groups
namely sham operation group
model group
the low dose group and the high dose group of Changweiqing. Sham operation group and model group were given normal saline
Changweiqing low and high dose groups were administrated with 10.37
20.74 g·kg-1 respectively. The HE staining was performed to judge liver metastasis. The expression of the CXCR4
CXCL12
and MMP9 was detected by immunohistochemistry and quantitative real-time PCR in the colorectal tumor tissues and the normal colon tissue. Result: The weight inhibition rates of colon in situ tumor in Changweiqing low and high dose groups were 24.73%
45.91%; while the volume inhibition rates were 27.93%
63.48%. The liver metastasis rates were 75%
37.5%
12.5% in the model group
Changweiqing low and high dose groups respectively. The CXCR4
CXCL12
MMP9 protein and mRNA expression of the colon tumor tissue in model group were significantly higher than that in the sham operation group (P<0.05)
while the low and high dose Changweiqing could reduce their expressions (P<0.05). CXCR4 protein and mRNA expression in Changweiqing low dose and high dose groups showed significant decrease compared with those in model group (P<0.05). CXCL12
protein expression in Changweiqing low dose and high dose groups was significantly decreased compared with that in the model group (P<0.05). CXCL12 mRNA in Changweiqng high dose group was significantly decreased compared with that in the model group (P<0.05). For MMP9 protein and mRNA expression
Changweiqing high dose could decrease them significantly compared with those in the model group (P<0.05). Conclusion: Changweiqing inhibits the colorectal cancer tumor growth in situ and the incidence of liver metastasis in mice
The mechanism is likely related to the down-regulation of CXCR4
Effect and Mechanism of Yiyi Fuzi Baijiangsan on Apoptosis of Human Colon Cancer HCT116 Cells
Efficacy and Mechanism of Chinese Medicinal Compounds and Monomers from Chinese Medicinals against Colorectal Cancer: A Review
Study on Anti-colorectal Cancer Mechanism of Gallic Acid Based on JAK/STAT Pathway
Effect of Jianpi Xiaoai Prescription on Activation of HFL1 into CAFs Induced by Exosomes in Colon Cancer
Effect of Tanshinone Ⅱ on Angiogenesis in Nude Mice with Colorectal Cancer
Related Author
LI Zhi
LIU Wei
LI Li
ZHOU Xin
ZOU Xin
YU Xia
FU Jiawei
BAI Jiaojiao
Related Institution
College of Integrated Traditional Chinese and Western Medicine,Southwest Medical University
Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
College of Pharmacy, Xinjiang Medical University
Graduate School, Hunan University of Chinese Medicine
Hunan Key Laboratory of Chinese Medicine Oncology, Innovative Platform of Antitumor Chinese Drugs, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital